TAB014

· BioDlink Biopharm Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TAB014, covering 2025-01-07 to 2025-01-07. Get the full timeline:

Most recent: Clinical Trial Update: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration [Phase 3]